The United States of America As Represented by the Department of Health

National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States of America As Represented by the Secretary of

The United States of America As Represented by the Secretary, Department

Edward J Leonard

Teizo Yoshimura

Ettore Appella

Kouji Matsushima

Stephen D Showalter

Elizabeth A Robinson

Joost Oppenheim

Joost J Oppenheim

Alison H Skeel

Appella Ettore

Ettore Appela

Yoshimura Teizo

Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. The cloning of full length cDNA for the peptide products is also provided, as well as recombinant methods for the production of monocyte chemoattractant products. Methods of treating infection and neoplasms in a human body with such peptides and monocyte chemoattractant products are additionally provided, as well as pharmaceutical compositions for the same.

Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof

An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto

An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity of NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Nucleic acids encoding a novel neutrophil chemotactic factor

Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with the peptide products are additionally provided, as well as pharmaceutical compositions for the peptide products.

Human derived monocyte attracting purified peptide products useful in a

An isloated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Method of treating inflammation with antibodies to neutrophil

Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with such peptides and monocyte chemoattractant products are additionally provided, as well as pharmaceutical compositions for the same.

Human derived monocyte attracting purified protein product useful in a

The present invention relates to an isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete coding sequence for NCF.

Antibodies specific for neutrophic chemotactic factor

Neutrophil chemotactic factor

Process for preparing human derived monocyte attracting purified peptide

A method of purifying macrophage stimulating protein. Antibodies to macrophage stimulating protein and a bioassay for the detection of antibodies which bind macrophage stimulating protein.

Antibodies to macrophage stimulating protein, bioassay and

The present invention relates to a method of purifying macrophage stimulating protein (MSP) and to the highly purified MSP. The present invention further relates to antibodies to MSP. The highly purified MSP may be used for fighting pathogen infections.

Growing community of inventors

Chevy Chase, MD, United States of America

Edward J Leonard